Filing Signals

Source: SEC EDGAR Compiled 2026-11-13 17:17 UTC 23 automated checks passing

← All events

Verastem, Inc.

CIK 1526119 VSTM·Pharmaceutical Preparations · All EDGAR filings ↗

Progression

  1. Revenue recognition change 10-K
  2. Going concern 10-Q +246d
Refine
Form
An amendment is grouped with the report it amends; every 12b-25 notice is one group

Going concern Filing comparison

Verastem, Inc. said management's plans alleviate substantial doubt about going concern

Substantial doubt about ability to continue as a going concern → Substantial doubt raised, alleviated by management's plans

The Company continues to incur operating costs to execute its strategic plan, including costs related to research and development of its product candidates and commercial execution activities. The Company’s increased cash and cash equivalents position as of September 30, 2026 plus net proceeds received from the Offering in October 2026 alleviated the substantial doubt. The Company expects to finance its operations with its existing cash, cash equivalents and investments, through future net product revenues, through potential future milestones and royalties received pursuant to the Company’s…
Evidence
Blank check
No
Comparable
Yes
Current state
doubt_alleviated
Current state label
Substantial doubt raised, alleviated by management's plans
Direction
eased
Located in
filing body
Prior filed
2026-08-06
Prior form
10-Q
Prior state
substantial_doubt
Prior state label
Substantial doubt about ability to continue as a going concern
Source
ASC 205-40 going-concern note comparison
Why
Disclosure about the company's ability to continue as a going concern changed compared with its previous report.
Revenue recognition change beta Filing comparison

Verastem, Inc. changed its revenue recognition disclosure

(iii) determine the F-15 Table of Contents transaction price;
Evidence
New language
(iii) determine the F-15 Table of Contents transaction price;, Product Revenue, Net - The Company sells AVMAPKI FAKZYNJA CO-PACK to a limited number of specialty pharmacies and specialty distributors in the United States.
Prior filed
2025-03-20
Prior form
10-K
Similarity
0.305
Source
revenue recognition note comparison
Threshold
0.6
Why
The revenue recognition policy disclosure changed materially from the previous comparable filing.

Language present now, absent from the prior filing:

  • (iii) determine the F-15 Table of Contents transaction price;
  • Product Revenue, Net - The Company sells AVMAPKI FAKZYNJA CO-PACK to a limited number of specialty pharmacies and specialty distributors in the United States.